---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-032156"
form_type: "8-K"
ticker: "FOXO"
cik: "0001812360"
company_name: "FOXO TECHNOLOGIES INC."
filed_at: "2026-07-06T20:05:39+00:00"
generated_at: "2026-07-06T20:07:28.127241+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FOXO Technologies mid-year update: Q1 revenue $5.1M, loss narrowed, potential $10M+ Vector acquisition

## Summary
- Q1 2026 net revenues $5.1M vs $3.2M YoY; operating loss narrowed to $0.3M from $1.5M.
- Effected 1:3,000 reverse stock split; exchanged ~$7.8M Series A Preferred into non-convertible debt to reduce dilution.
- Entered agreement with former CEO Jon Sabes to license epigenetics IP for 3% royalty (cap $1.3M) and ten-year option for majority ownership.
- Myrtle Recovery Centers operating at 92% occupancy; seeking expansion to 32 beds; annualized admissions ~700 in 2026.
- Vector BioSource evaluating acquisition that could add >$10M annual revenue; company considering uplisting to NYSE American.

## SEC filing metadata
- accession: 0001493152-26-032156
- form_type: 8-K
- ticker: FOXO
- cik: 0001812360
- company_name: FOXO TECHNOLOGIES INC.
- filed_at: 2026-07-06T20:05:39+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812360/000149315226032156/0001493152-26-032156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812360/000149315226032156/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-032156
- JSON: https://secwatch.observer/filing/0001493152-26-032156.json
- Plain text: https://secwatch.observer/filing/0001493152-26-032156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.